Inari Medical to Announce Second Quarter 2021 Financial Results
Inari Medical, Inc. (NASDAQ: NARI) will announce its second quarter financial results on August 10, 2021. A conference call and webcast will follow at 1:30 p.m. PT to discuss the results and updates. Inari is known for its innovative medical devices aimed at treating venous diseases, including the ClotTriever and FlowTriever systems, both approved by the FDA and CE Mark for deep vein thrombosis and pulmonary embolism treatments, respectively. The company's focus remains on transforming patient care in venous thromboembolism.
- Innovative products like ClotTriever and FlowTriever approved by FDA and CE Mark.
- Focus on transforming patient care in venous diseases.
- None.
IRVINE, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release its second quarter financial results on Tuesday, August 10, 2021. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live call via telephone by dialing (833)-519-1265 for domestic callers or (914)-800-3838 for international callers, using conference ID: 1160795. The live webinar of the call may be accessed by visiting the Events Section of the Inari investor relations website at ir.inarimedical.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari’s website.
About Inari Medical, Inc.
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium.
Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com
FAQ
When will Inari Medical release its Q2 2021 earnings?
What products does Inari Medical offer for venous diseases?
How can I access the Inari Medical earnings call?
What time is the Inari Medical earnings call scheduled?
